These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 20682393)

  • 1. Number of somatic mutations in the mitochondrial D-loop region indicates poor prognosis in breast cancer, independent of TP53 mutation.
    Kuo SJ; Chen M; Ma GC; Chen ST; Chang SP; Lin WY; Chen YC; Lee TH; Lin TT; Liu CS
    Cancer Genet Cytogenet; 2010 Sep; 201(2):94-101. PubMed ID: 20682393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer.
    Tseng LM; Yin PH; Chi CW; Hsu CY; Wu CW; Lee LM; Wei YH; Lee HC
    Genes Chromosomes Cancer; 2006 Jul; 45(7):629-38. PubMed ID: 16568452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
    Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
    Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients.
    Yu M; Zhou Y; Shi Y; Ning L; Yang Y; Wei X; Zhang N; Hao X; Niu R
    IUBMB Life; 2007 Jul; 59(7):450-7. PubMed ID: 17654121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid.
    Zhu W; Qin W; Bradley P; Wessel A; Puckett CL; Sauter ER
    Carcinogenesis; 2005 Jan; 26(1):145-52. PubMed ID: 15375011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer.
    Tan DJ; Bai RK; Wong LJ
    Cancer Res; 2002 Feb; 62(4):972-6. PubMed ID: 11861366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of mitochondrial mutations in colorectal cancer.
    Lièvre A; Chapusot C; Bouvier AM; Zinzindohoué F; Piard F; Roignot P; Arnould L; Beaune P; Faivre J; Laurent-Puig P
    J Clin Oncol; 2005 May; 23(15):3517-25. PubMed ID: 15908662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutations of the mitochondrial genome in human breast cancers.
    Tseng LM; Yin PH; Yang CW; Tsai YF; Hsu CY; Chi CW; Lee HC
    Genes Chromosomes Cancer; 2011 Oct; 50(10):800-11. PubMed ID: 21748819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma.
    Lee HC; Li SH; Lin JC; Wu CC; Yeh DC; Wei YH
    Mutat Res; 2004 Mar; 547(1-2):71-8. PubMed ID: 15013701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations.
    Barekati Z; Radpour R; Kohler C; Zhang B; Toniolo P; Lenner P; Lv Q; Zheng H; Zhong XY
    Hum Mol Genet; 2010 Aug; 19(15):2936-46. PubMed ID: 20466735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of mitochondrial DNA D-loop mutations and p53 status in nonmelanoma skin cancer.
    Prior SL; Griffiths AP; Lewis PD
    Br J Dermatol; 2009 Nov; 161(5):1067-71. PubMed ID: 19624548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between clinical characteristics and mitochondrial D-loop DNA mutations in hepatocellular carcinoma.
    Tamori A; Nishiguchi S; Nishikawa M; Kubo S; Koh N; Hirohashi K; Shiomi S; Inoue M
    J Gastroenterol; 2004 Nov; 39(11):1063-8. PubMed ID: 15580399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of mitochondrial DNA as potential biomarkers in breast cancer.
    Cai FF; Kohler C; Zhang B; Chen WJ; Barekati Z; Garritsen HS; Lenner P; Toniolo P; Zhang JJ; Zhong XY
    Anticancer Res; 2011 Dec; 31(12):4267-71. PubMed ID: 22199290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial DNA D-loop in pancreatic cancer: somatic mutations are epiphenomena while the germline 16519 T variant worsens metabolism and outcome.
    Navaglia F; Basso D; Fogar P; Sperti C; Greco E; Zambon CF; Stranges A; Falda A; Pizzi S; Parenti A; Pedrazzoli S; Plebani M
    Am J Clin Pathol; 2006 Oct; 126(4):593-601. PubMed ID: 16938655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
    Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
    Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.